Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ART022
MIFTS: 71

Arthritis

Categories: Bone diseases, Genetic diseases, Immune diseases, Liver diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Arthritis

About this section

MalaCards integrated aliases for Arthritis:

Name: Arthritis 12 74 29 54 6 42 3 44 15 37 17 71
Inflammatory Joint Disease 54 71
Inflammatory Disorder of Joint 12

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Bone diseases Immune diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:848
MeSH 44 D001168
NCIt 50 C2883
SNOMED-CT 67 372091005
UMLS 71 C0003864 C0683381
Sources

Summaries for Arthritis

About this section
MedlinePlus : 42 If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Arthritis, also known as inflammatory joint disease, is related to rheumatoid arthritis and juvenile rheumatoid arthritis, and has symptoms including joint stiffness, back pain and arthralgia. An important gene associated with Arthritis is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Naltrexone and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include joint, bone and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located in joint.

CDC : 3 Arthritis means inflammation or swelling of one or more joints. It describes more than 100 conditions that affect the joints, tissues around the joint, and other connective tissues. Specific symptoms vary depending on the type of arthritis, but usually include joint pain and stiffness.

Wikipedia : 74 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Sources

Related Diseases for Arthritis

About this section

Diseases in the Arthritis family:

Juvenile Arthritis Transient Arthritis

Diseases related to Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2537)
# Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 34.3 TNFSF11 TNF SYK PTPN22 MMP3 MMP13
2 juvenile rheumatoid arthritis 34.2 TNF LTA IL6 IL1B IL10 HLA-DRB1
3 psoriatic arthritis 34.2 TNFSF11 TNF PTPN22 NOD2 MMP3 MMP1
4 reactive arthritis 33.8 TNF IL6 IL1B IL17A IL10 HLA-DRB1
5 spondyloarthropathy 1 33.6 TNFSF11 TNF NOD2 MMP3 IL6 IL17A
6 osteoarthritis 33.6 TNFSF11 TNF MMP3 MMP13 MMP1 IL6
7 systemic onset juvenile idiopathic arthritis 33.6 TNF LACC1 IL6 HLA-DRB1
8 juvenile arthritis 33.6 LACC1 IL6 IL10
9 psoriasis 33.4 TNF PTPN22 NOD2 LTA IL6 IL1B
10 psoriatic juvenile idiopathic arthritis 33.3 PSTPIP1 NOD2
11 blau syndrome 33.3 TNF NOD2 IL1B IL10
12 oligoarticular juvenile idiopathic arthritis 33.0 TNF PTPN22 HLA-DRB1
13 lyme disease 33.0 TNF IL6 IL1B IL17A HLA-DRB1
14 systemic lupus erythematosus 32.9 TNF SYK PTPN22 NOD2 MMP3 LTA
15 palindromic rheumatism 32.9 TNF PTPN22 IL1B HLA-DRB1
16 behcet syndrome 32.9 TNF PTPN22 PSTPIP1 NOD2 LTA IL6
17 spondylitis 32.9 TNFSF11 TNF NOD2 LTA IL6 IL1B
18 fibromyalgia 32.8 TNF IL6 IL1B IL10 CCL2
19 osteoporosis 32.8 TNFSF11 TNF MMP3 MMP1 IL6 IL1B
20 connective tissue disease 32.8 TNFSF11 TNF MMP3 MMP13 IL6 IL1B
21 transient arthritis 32.8 IL6 IL1B IL17A
22 autoimmune disease 32.8 TNF SYK PTPN22 LTA IL6 IL1B
23 interstitial lung disease 32.8 TNF IL6 IL1B IL1A IL17A IL10
24 polyarticular juvenile idiopathic arthritis 32.8 TNF LACC1
25 adult-onset still's disease 32.8 TNF IL6 IL1B HLA-DRB1
26 pustulosis of palm and sole 32.7 TNF PSTPIP1 IL17A
27 systemic scleroderma 32.7 TNF IL6 IL17A IL10
28 arthropathy 32.7 TNFSF11 TNF MMP3 MMP13 MMP1 LTA
29 paget's disease of bone 32.6 TNFSF11 TNF IL6
30 back pain 32.6 IL6 IL1B IL1A
31 temporal arteritis 32.6 TNF PTPN22 IL6 IL1B IL17A HLA-DRB1
32 synovitis 32.6 TNFSF11 TNF RELN MMP3 MMP13 MMP1
33 uveitis 32.6 TNF NOD2 LTA IL6 IL1B IL1A
34 sarcoidosis 1 32.6 TNF NOD2 LTA IL1B IL1A HLA-DRB1
35 carpal tunnel syndrome 32.6 IL6 IL1B CCL2
36 multicentric carpotarsal osteolysis syndrome 32.6 TNFSF11 TNF IL6 IL1B
37 mixed connective tissue disease 32.6 TNF IL6 IL10 HLA-DRB1
38 dermatitis 32.6 TNF NOD2 IL6 IL1B IL1A IL17A
39 familial mediterranean fever 32.6 TNF PSTPIP1 NOD2 IL6 IL1B IL1A
40 brucellosis 32.6 TNF PTPN22 IL6 IL17A IL10
41 bursitis 32.6 TNF MMP3 IL6 IL1B
42 bone disease 32.6 TNFSF11 TNF MMP13 LTA IL6 IL1B
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 32.5 PTPN22 IL17A IL10
44 rheumatoid factor-negative polyarticular juvenile idiopathic arthritis 32.5 PTPN22 LACC1
45 osteomyelitis 32.5 TNFSF11 TNF NOD2 IL6 IL1B IL1A
46 cartilage disease 32.5 TNF MMP3 MMP13 IL6 IL1B
47 osteonecrosis 32.5 TNFSF11 TNF IL1B
48 acne 32.5 TNF PSTPIP1 IL6 IL1B IL1A
49 lung disease 32.5 TNF IL6 IL1B IL1A IL17A IL10
50 vasculitis 32.5 TNF IL6 IL17A CCL2

Graphical network of the top 20 diseases related to Arthritis:



Diseases related to Arthritis
Sources

Symptoms & Phenotypes for Arthritis

About this section

UMLS symptoms related to Arthritis:


joint stiffness, back pain, arthralgia, sciatica, muscle cramp, metatarsalgia

GenomeRNAi Phenotypes related to Arthritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 IL10 IL17A IL1A IL1B LTA RELN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 IL10 IL17A IL1B LTA NOD2 RELN

MGI Mouse Phenotypes related to Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 IL10 IL17A IL1A IL1B IL6 LACC1
2 immune system MP:0005387 10.28 CCL2 CPT2 IL10 IL17A IL1A IL1B
3 homeostasis/metabolism MP:0005376 10.27 CPT2 IL10 IL17A IL1A IL1B IL6
4 integument MP:0010771 9.91 IL10 IL17A IL1A IL1B IL6 MMP13
5 neoplasm MP:0002006 9.7 IL10 IL1A IL1B IL6 MMP1 TNF
6 respiratory system MP:0005388 9.61 CPT2 IL10 IL17A IL6 LTA PTPN22
7 skeleton MP:0005390 9.4 CPT2 IL10 IL17A IL1B IL6 LTA
Sources

Drugs & Therapeutics for Arthritis

About this section

Drugs for Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 710)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
2
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
4
Famotidine Approved Phase 4 76824-35-6 3325
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
7
Norepinephrine Approved Phase 4 51-41-2 439260
8 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
9
Calcium carbonate Approved, Investigational Phase 4 471-34-1
10
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
11
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
12
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
13
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051
15
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
16
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
17
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
18
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
19 Brodalumab Approved, Investigational Phase 4 1174395-19-7
20
Simvastatin Approved Phase 4 79902-63-9 54454
21
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
22
Pheniramine Approved Phase 4 86-21-5 4761
23
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
24
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
25
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
26
Promethazine Approved, Investigational Phase 4 60-87-7 4927
27
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
28
Ticagrelor Approved Phase 4 274693-27-5 9871419
29
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
30
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
31
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
32
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
33
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
34
Dalteparin Approved Phase 4 9005-49-6
35
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
36
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
37
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
38
Prilocaine Approved Phase 4 721-50-6 4906
39
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
40
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
41
Desflurane Approved Phase 4 57041-67-5 42113
42
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
45
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
46
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
47
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
48
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
49
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
50
Ravulizumab Approved, Investigational Phase 4 1803171-55-2

Interventional clinical trials:

(show top 50) (show all 3638)
# Name Status NCT ID Phase Drugs
1 Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease Unknown status NCT01893996 Phase 4 Adalimumab;Placebo
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Prospective Clinical Study to Observe the Efficacy and Safety of Iguratimod in Rheumatoid Arthritis and Early Rheumatoid Arthritis Patients for 6 Months Treatment in China Unknown status NCT03855007 Phase 4 Iguratimod;MTX;HCQ;Pred
4 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
5 A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis Unknown status NCT00808496 Phase 4
6 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
7 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
8 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
9 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
10 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis. Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
11 A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis Unknown status NCT02659150 Phase 4 tocilizumab
12 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
13 Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate Unknown status NCT02714634 Phase 4 Methotrexate + biologic administration;methotrexate + salazopyrine + hydroxychloroquine administration
14 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
15 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
16 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
17 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
18 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
19 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
20 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
21 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
22 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
23 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
24 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
25 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
26 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
27 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
28 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
29 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
30 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
31 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
32 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
33 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Unknown status NCT03781310 Phase 4 Tocilizumab
34 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
35 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
36 NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease Unknown status NCT03699293 Phase 4 celecoxib 200mg capsule;naproxen sodium 550mg tablet;Aspirin 81mg tablet
37 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
38 Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis. Unknown status NCT02242474 Phase 4 Anti-TNF suspended perioperatively;Anti-TNFα continued perioperatively
39 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
40 Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population? Unknown status NCT02936180 Phase 4
41 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
42 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
43 Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study Unknown status NCT00552136 Phase 4
44 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
45 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
46 The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis. Unknown status NCT00513422 Phase 4
47 Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing) Unknown status NCT00180206 Phase 4
48 Corticosteroids as Additive in Arthrocentesis of the Temporomandibular Joint: Double Blind, Randomised Controlled Trial of Effectiveness. Unknown status NCT01275014 Phase 4 Dexamethasone;Isotonic saline
49 Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study Unknown status NCT01623687 Phase 4
50 Gait Analysis of Patients Undergoing Total Ankle Arthroplasty, Ankle Arthrodesis, Tibiotalocalcaneal or Pantalar Fusion. Unknown status NCT00921076 Phase 4

Search NIH Clinical Center for Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Devil's claw preparation
Meclofenamate
Meclofenamate Sodium
Salsalate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Arthritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Arthritis:
AlloStem, adipose-derived mesenchymal stem cells combined with allograft bone for bone grafting
Embryonic/Adult Cultured Cells Related to Arthritis:
Adipose-derived mesenchymal stem cells combined with allograft bone (AlloStem) PMIDs: 22500696

Cochrane evidence based reviews: arthritis

Sources

Genetic Tests for Arthritis

About this section

Genetic tests related to Arthritis:

# Genetic test Affiliating Genes
1 Arthritis 29
Sources

Anatomical Context for Arthritis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Arthritis:

19
Joint

MalaCards organs/tissues related to Arthritis:

40
Bone, T Cells, Endothelial, Skin, B Cells, Bone Marrow, Neutrophil
Sources

Publications for Arthritis

About this section

Articles related to Arthritis:

(show top 50) (show all 32152)
# Title Authors PMID Year
1
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. 42 61
33380344 2020
2
Axial spondyloarthritis: new advances in diagnosis and management. 42
33397652 2021
3
Efficacy and safety of warm acupuncture in the treatment of ankylosing spondylitis: A protocol for systematic review and meta-analysis. 42
33429781 2021
4
Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. 54 61
20447852 2010
5
Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. 61 54
19533138 2010
6
Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. 61 54
19732956 2009
7
Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. 54 61
19644886 2009
8
Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. 54 61
19052752 2009
9
Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis. 54 61
19660107 2009
10
Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? 61 54
19327240 2009
11
Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. 61 54
19035519 2008
12
Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. 54 61
18674945 2008
13
The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. 54 61
18602896 2008
14
IL-33 exacerbates antigen-induced arthritis by activating mast cells. 54 61
18667700 2008
15
Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. 54 61
18612926 2008
16
Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. 54 61
17728335 2008
17
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. 54 61
18321234 2008
18
EBV-specific T-cell response and immunosuppression by methotrexate and TNFalpha antagonists in patients with chronic inflammatory joint disease. 61 54
17988922 2007
19
The immunology of rheumatoid arthritis. 54 61
17893995 2007
20
Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. 61 54
17565662 2007
21
No evidence for genetic association of interferon regulatory factor 1 in juvenile idiopathic arthritis. 54 61
17328074 2007
22
TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. 54 61
17368068 2007
23
Use of infliximab to treat psoriatic arthritis in HIV-positive patients. 61 54
17321777 2007
24
Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. 54 61
17265479 2007
25
Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. 61 54
17127088 2006
26
Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. 61 54
17038468 2006
27
Histamine induces interleukin-6 expression in the human synovial sarcoma cell line (SW982) through the H1 receptor. 61 54
17122961 2006
28
Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. 61 54
16133581 2006
29
Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. 54 61
16107514 2006
30
Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. 54 61
16096332 2006
31
Osteoclasts; culprits in inflammatory osteolysis. 54 61
16356195 2006
32
Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. 54 61
16332240 2005
33
Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses. 61 54
15972692 2005
34
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. 61 54
15934099 2005
35
Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. 61 54
15769927 2005
36
Bone marrow cells carrying the env-pX transgene play a role in the severity but not prolongation of arthritis in human T-cell leukaemia virus type-I transgenic rats: a possible role of articular tissues carrying the transgene in the prolongation of arthritis. 54 61
15312124 2004
37
Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. 54 61
15466401 2004
38
Secretion of oncostatin M by neutrophils in rheumatoid arthritis. 54 61
15146412 2004
39
Membrane-associated IL-1 contributes to chronic synovitis and cartilage destruction in human IL-1 alpha transgenic mice. 54 61
14688369 2004
40
The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. 54 61
14613283 2003
41
Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. 61 54
12904891 2003
42
Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. 61 54
12798660 2003
43
Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. 54 61
12662147 2003
44
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. 61 54
12384938 2002
45
The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. 61 54
12193736 2002
46
Mice lacking endogenous major histocompatibility complex class II develop arthritis resembling psoriatic arthritis at an advanced age. 61 54
12355495 2002
47
Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. 54 61
12355506 2002
48
B cells and immunoglobulins dependent mechanisms in rheumatoid arthritis: a possible rationale of the extracorporeal immunomodulation for rheumatoid arthritis. 54 61
12164803 2002
49
Pro-inflammatory role of serotonin and interleukin-6 in arthritis and spondyloarthropathies--measurement of disease activity by bone scan and effect of steroids. 61 54
11922199 2002
50
Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? 61 54
11748257 2001
Sources

Variations for Arthritis

About this section

ClinVar genetic disease variations for Arthritis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic 989389 9:93650098-93650098 9:90887816-90887816
2 CPT2 NM_000098.3(CPT2):c.149C>A (p.Pro50His) SNV Pathogenic 8954 rs28936375 1:53662764-53662764 1:53197092-53197092
3 RELN NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly) SNV Pathogenic 684430 rs760019076 7:103163872-10316